BioBridgeX
Log inCompare quotes
Modality

Radiopharmaceutical / Radioligand CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing a radiopharmaceutical or radioligand program means buying radiochemistry, radiolabeling, and shielded GMP manufacturing that run on a decay clock, plus radiation-licensed sites, dosimetry, and isotope supply. It needs CROs and CDMOs with hot cells, isotope sourcing, and release QC fast enough to ship before the dose decays. On BioBridgeX, buyers source and compare qualified suppliers, then contract directly with their chosen supplier, free for buyers.

Radiopharmaceutical / Radioligand CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Radiopharmaceutical / Radioligand CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What does it take to develop and manufacture a Radiopharmaceutical / Radioligand drug?

Radiopharmaceuticals are two molecules doing one job: a targeting ligand (a small molecule, peptide, or antibody) bonded through a chelator or covalent linker to a radioactive isotope that either images disease or kills the cell it lands on. That second half is what makes this modality unlike anything else you will outsource. The product is radioactive, it is decaying from the moment it is made, and a lot of your development timeline is governed by a half-life rather than a Gantt chart. A Lu-177 therapy gives you days of working window; a Ga-68 or F-18 PET tracer gives you hours. Ac-225 and other alpha emitters add their own handling and daughter-isotope headaches. None of that is negotiable, and it shapes every supplier decision downstream.

On the discovery and preclinical side the work looks partly familiar and partly specialized. You need medicinal chemistry to build and optimize the targeting vector, then chelator chemistry (DOTA, DOTAGA, NOTA, and the rest) or site-specific conjugation to attach the payload without wrecking binding affinity. Then comes radiolabeling chemistry, where the team works out labeling conditions, radiochemical yield, and radiochemical purity, and biodistribution and dosimetry studies in animals to see where the activity goes and how much hits off-target tissue (kidney and bone marrow uptake are the usual worries). Autoradiography, SPECT/PET imaging, and a real understanding of theranostic pairing, using the same vector with a diagnostic isotope to image and a therapeutic isotope to treat, separate teams who have done this from teams reading about it.

CMC and manufacturing is where generalist CDMOs fall away. You cannot make this product in an ordinary fill-finish suite. Radiopharma manufacturing happens in shielded hot cells and isolators, behind lead, often with automated synthesis modules so operators are not standing next to the activity. The site has to hold a radioactive materials license (NRC or an Agreement State, equivalent abroad) on top of GMP, run radiation safety and ALARA programs, and manage radioactive waste. Then there is the QC problem that defines the whole field: you have to complete sterility-relevant and identity, radiochemical purity, and radionuclidic purity testing and release the batch before it decays below a usable dose, so analytical methods are validated for speed as much as accuracy, and some release happens on a rapid or parametric basis with confirmatory testing after the dose has already shipped. Specialist radiopharmaceutical CDMOs are built around isotope supply contracts, decentralized or centralized dose production near the clinic, and cold-chain-plus-decay logistics. A generalist simply is not set up for any of it.

How do you choose a CRO or CDMO for Radiopharmaceutical / Radioligand?

Supplier fit in this modality is narrower than almost any other, because the equipment, licenses, and isotope relationships take years to build and cannot be improvised for your project. Work through this checklist before you shortlist, and weight isotope access and licensing heavily: a brilliant radiochemistry team with no reliable supply of your isotope cannot run your program.

  • Relevant platform and track record: have they actually labeled and released your isotope class (Lu-177, Ac-225, I-131, Ga-68, F-18, Cu-64, others), with the specific chelator or conjugation chemistry your vector uses? Ask for programs they have taken from labeling development through GMP batches.
  • Isotope supply and sourcing: where do they get the isotope, is the supply contracted and redundant, and can they meet your dose schedule given the half-life? Sole-source isotope risk has stalled real programs, so this question comes first, not last.
  • GxP and analytical capability for this modality: shielded hot cells or isolators, automated synthesis modules, radiation-licensed GMP site, plus QC methods validated for radiochemical purity, radionuclidic purity, and rapid release on a decay clock. Confirm sterility approach for a product you cannot fully test before shipping.
  • Regulatory experience: a documented history with radiopharmaceutical INDs and NDAs, dosimetry packages, and the radiation safety and licensing layer that sits on top of normal GMP. Experience with theranostic pairing filings is a plus if that is your strategy.
  • Capacity and scale: can they go from a handful of preclinical labelings to clinical doses to commercial supply without you re-qualifying a new site mid-program? Ask about batch frequency, hot-cell availability, and whether they run decentralized production near trial sites.
  • Dosimetry and preclinical depth (if sourcing earlier work): biodistribution, dosimetry modeling, autoradiography, and imaging readouts that will actually support your IND, not just internal data.
  • IP, confidentiality, and freedom to operate: clear ownership of labeling methods and process know-how, watertight confidentiality given how small and interconnected this field is, and a check that their chelator or linker chemistry does not drag in third-party IP.

Frequently asked questions

What is the difference between a CRO and a CDMO for a radiopharmaceutical program?
A CRO runs the science: medicinal and radiochemistry, labeling development, biodistribution, dosimetry, and imaging studies that build your preclinical and IND package. A CDMO makes the actual product under GMP in shielded facilities and releases clinical or commercial doses. In radiopharma the line blurs more than usual, because labeling development and manufacturing both depend on the same hot cells and isotope supply, so some specialist suppliers do both. On BioBridgeX you can source across both functions, comparing quotes and contracting directly with your chosen suppliers, in one place.
Why is the isotope half-life such a big deal when picking a supplier?
Because the product is decaying the entire time. With a Ga-68 or F-18 PET tracer you may have only a few hours from synthesis to injection, so the supplier has to manufacture, run QC, release, and ship within that window, sometimes producing the dose near the clinic. Even a longer-lived therapeutic isotope like Lu-177 (roughly 6.6-day half-life) constrains batch timing and logistics. A supplier whose location, batch frequency, and release testing do not fit your isotope's clock cannot serve your program, no matter how strong the chemistry is.
Do I need a supplier with a radioactive materials license, or is GMP enough?
You need both, and the radiation licensing sits on top of GMP, it does not replace it. A radiopharmaceutical manufacturing site holds a radioactive materials license from the NRC or an Agreement State (equivalent regulators apply outside the US), runs radiation safety and ALARA programs, and manages radioactive waste, all in addition to standard GMP for sterile injectables. A site with excellent GMP but no radiation license, hot cells, or isotope handling capability simply cannot make this product.
What does the QC and batch release look like when the dose is decaying before testing finishes?
It is one of the defining challenges of the modality. You test identity, radiochemical purity, radionuclidic purity, and sterility-relevant attributes, but the methods have to be fast, because the dose loses potency and may be administered before every result is back. Short-lived products often release on a rapid or parametric basis with some confirmatory testing completed after the dose has shipped, under a validated, regulator-accepted process. Ask any supplier exactly how they handle release timing for your isotope before you commit.
What is a theranostic pairing and does it change how I scope suppliers?
A theranostic uses the same targeting vector with two different isotopes: a diagnostic one (such as Ga-68) to image where the drug goes and which patients will respond, and a therapeutic one (such as Lu-177 or Ac-225) to treat. If that is your strategy you want a supplier comfortable labeling and supplying both arms and supporting the imaging and patient-selection data your regulators will expect. It widens the scope of what you are sourcing, which is another reason to compare quotes and contract directly with your chosen suppliers in one place rather than chasing separate diagnostic and therapeutic suppliers.
How does BioBridgeX make sourcing radiopharmaceutical suppliers easier and what does it cost me?
BioBridgeX is free for buyers. You describe what you need, get matched with qualified radiopharmaceutical and radioligand CROs and CDMOs, compare them on the things that actually matter here (isotope access, licensing, hot-cell capacity, release approach), and contract directly with the suppliers you choose, in one place. BioBridgeX acts as the neutral marketplace and charges a flat 2% fee to the supplier, not to you, so the platform stays neutral on which supplier you choose.

Source Radiopharmaceutical / Radioligand work with one contract

Compare transparent quotes from qualified Radiopharmaceutical / Radioligand CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes